跳至主要内容
临床试验/NCT02119520
NCT02119520已完成2 期

PLATELET RICH FIBRIN COMBINED WITH 1.2% ATORVASTATIN FOR TREATMENT OF INTRABONY DEFECTS IN CHRONIC PERIODONTITIS

Government Dental College and Research Institute, Bangalore1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
96
试验地点
1
主要终点
Percentage radiographic defect depth reduction

研究概览

简要总结

Current study was designed to evaluate the combined efficacy of PRF and 1.2% ATV gel with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • the presence of 3- wall IBD ≥3 mm deep (distance between alveolar crest and base of the defect on an intraoral periapical radiograph [IOPA]) along with an interproximal probing depth (PD) ≥5 mm after phase I therapy (scaling and root planing [SRP]) in asymptomatic teeth.

排除标准

  • Agressive Periodontitis subjects; 2) Systemic conditions known to affect the periodontal status; 3) medications known to affect the outcomes of periodontal therapy; 4) Hematological disorders and insufficient platelet count (<200,000/mm3); 5) pregnancy/lactation; and 6) Smoking and tobacco use in any form 7) Immunocompromised individuals.

研究组 & 干预措施

Platelet rich fibrin + atorvastatin

Active Comparator

In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD

干预措施: Platelet rich fibrin +Atorvastatin (Drug)

Open flap debridement

Other

open flap debridement was followed by no grafting or regenerative intervention.

干预措施: open flap debridement (Procedure)

Platelet rich fibrin

Sham Comparator

In Platelet rich fibrin group PRF was inserted into the depth of the IBD.

干预措施: Platelet rich fibrin (Drug)

结局指标

主要结局

Percentage radiographic defect depth reduction

时间窗: 9 months from baseline

Defect depth reduction will be assessed from baseline to 9 month post operatively on radiographs

次要结局

  • change in probing depth(9 months from baseline)
  • change in relative attachment level(9 months from baseline)
  • change in plaque levels(9 months from baseline)
  • change in gingival bleeding(9 months from baseline)
  • change in gingival margin levels(9 months from baseline)

研究者

发起方
Government Dental College and Research Institute, Bangalore
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. A R Pradeep

Professor

Government Dental College and Research Institute, Bangalore

研究点 (1)

Loading locations...

相似试验

已完成
1 期
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant GliomaAdult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaRecurrent Adult Brain Tumor
NCT00650923National Cancer Institute (NCI)61
已完成
2 期
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial CancerRecurrent Endometrial Carcinoma
NCT00462826National Cancer Institute (NCI)49
已完成
1 期
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube CancerStage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7
NCT01749397National Cancer Institute (NCI)29
已完成
1 期
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasAnaplastic AstrocytomaChildhood Mixed GliomaFibrillary AstrocytomaGiant Cell GlioblastomaGliosarcomaUntreated Childhood Anaplastic AstrocytomaUntreated Childhood Brain Stem GliomaUntreated Childhood Fibrillary AstrocytomaUntreated Childhood Giant Cell GlioblastomaUntreated Childhood GlioblastomaUntreated Childhood GliosarcomaGlioblastomaBrain Stem Glioma
NCT01514201National Cancer Institute (NCI)66
进行中(未招募)
2 期
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast CancerBreast Cancer
NCT02955394University of Colorado, Denver61